| Code | CSB-RA025270MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to NI-006, targeting transthyretin (TTR), a homotetrameric protein primarily synthesized in the liver and choroid plexus. TTR functions as a transport protein for thyroxine (T4) and retinol-binding protein in plasma and cerebrospinal fluid. Mutations in the TTR gene or age-related protein misfolding can lead to TTR amyloidosis, a group of progressive disorders characterized by the extracellular deposition of amyloid fibrils in various tissues. These conditions include familial amyloid polyneuropathy, familial amyloid cardiomyopathy, and wild-type TTR amyloidosis, which collectively cause severe neuropathy, cardiomyopathy, and multi-organ dysfunction.
NI-006 represents an investigational therapeutic antibody designed to target TTR and has been explored in preclinical and clinical research for TTR amyloidosis. This biosimilar antibody provides researchers with a valuable tool for studying TTR biology, protein aggregation mechanisms, amyloid formation pathways, and potential therapeutic interventions. It supports investigations into disease pathogenesis, biomarker development, and the evaluation of novel treatment strategies for TTR-related amyloidoses.
There are currently no reviews for this product.